Apr 28, 2026 07:00AM FDA accepts drug application for zipalertinib lung cancer treatment

Mar 24, 2026 03:02PM Clear Street Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Mar 10, 2026 09:18AM Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Stifel

Mar 10, 2026 08:39AM Cullinan Oncology, Inc. (CGEM) Tops Q4 EPS by 1c

Feb 2, 2026 02:22AM Guggenheim Starts Cullinan Oncology Inc. (CGEM) at Buy

Jan 8, 2026 07:05AM Cullinan Therapeutics outlines 2026 milestones, reports $439M cash

Dec 17, 2025 08:20AM TD Cowen on Cullinan Oncology Inc. (CGEM): 'Full Speed Ahead In AML'

Dec 9, 2025 10:56AM Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Leerink Partners

Dec 8, 2025 10:34AM Cullinan Therapeutics reports clinical trial results for AML drug CLN-049

Nov 26, 2025 09:45AM Cullinan Oncology Inc. (CGEM) PT Raised to $36 at Jones Trading

Nov 25, 2025 04:19AM Cullinan Oncology Inc. (CGEM) PT Raised to $38 at BTIG

Nov 24, 2025 05:06AM Cullinan Therapeutics (CGEM) spreader of 5K contracts of December 9 and 15 calls

Nov 21, 2025 06:40AM Cullinan Oncology Inc. (CGEM) PT Raised to $26 at H.C. Wainwright

Nov 20, 2025 07:13AM Taiho Oncology, partners begin rolling FDA submission for lung cancer drug

Nov 6, 2025 08:17AM Cullinan Oncology, Inc. (CGEM) Tops Q3 EPS by 18c

Sep 12, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Sep 5, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Aug 21, 2025 06:35AM H.C. Wainwright Assumes Cullinan Oncology Inc. (CGEM) at Buy

Aug 7, 2025 09:43AM Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 25c

Jul 22, 2025 07:01AM Taiho Oncology and Cullinan to present zipalertinib data at lung cancer conference

Jul 3, 2025 06:12AM Clear Street Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Jun 4, 2025 04:03PM Cullinan Therapeutics (CGEM) Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

May 8, 2025 05:11PM Cullinan Oncology, Inc. (CGEM) Tops Q1 EPS by 8c

Apr 29, 2025 07:03AM Cullinan Therapeutics (CGEM) to Initiate Study of CLN-978

Apr 16, 2025 07:00AM Cullinan Therapeutics (CGEM) Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978

Mar 3, 2025 06:02AM Cullinan Oncology, Inc. (CGEM) Tops Q4 EPS by 6c

Jan 30, 2025 06:39AM Cullinan Oncology Inc. (CGEM) PT Raised to $33 at H.C. Wainwright

Dec 12, 2024 01:17PM Clear Street Starts Cullinan Oncology Inc. (CGEM) at Buy

Nov 14, 2024 10:01AM Cullinan Therapeutics (CGEM) Announces Preclinical Data for CLN-978

Oct 29, 2024 04:28PM BTIG Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Oct 24, 2024 03:46AM UBS Starts Cullinan Oncology Inc. (CGEM) at Buy

Oct 17, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Oct 16, 2024 07:00AM Cullinan Therapeutics (CGEM) Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978

Sep 18, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Sep 18, 2024 06:20AM BTIG Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Sep 17, 2024 07:00AM Cullinan Therapeutics (CGEM) Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Sep 16, 2024 08:51AM TD Cowen Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Sep 16, 2024 07:08AM H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Sep 16, 2024 07:02AM Cullinan Therapeutics (CGEM) Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Aug 8, 2024 11:56AM Cullinan Oncology Inc. (CGEM) PT Lowered to $38 at Morgan Stanley

Aug 8, 2024 08:24AM Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 2c